FDA ENDS 5TH QPPV TRAINING PROGRAM

The Food and Drugs Authority has concluded the Fifth (5th) Training Programme for Qualified Persons for Pharmacovigilance (QPPV) for Managers of the Local Pharmaceutical Industry.

In all, thirty-four (34) representatives from the local pharmaceutical industry were trained over a period of Nine (9) working days. The training was to ensure that representatives of medicine manufacturing and importing companies are trained to meet their legal obligations for the monitoring of the safety of their medicinal products on the market as specified in the Guideline on Good Pharmacovigilance Practices.

Dr. June Raine, a much- sought after Consultant in Phamarcovigilance, who is the Director of Vigilance and Risk Management at the Medicines and Healthcare products Regulatory Agency (MHRA) United Kingdom and the Chair of the Pharmacovigilance Risk Assessment Committee (PRAC) at the European Medicines Agency and also a member of the WHO Advisory Committee on Safety of Medicinal Products, gave the participants an overview of how the MHRA goes about its Pharmacovigilance activities

In her closing remarks, Dr. June Raine commended the FDA on the excellent work being done as a Regulator and most importantly in Pharmacovigilance. Dr. Raine also said she is highly impressed by the exceptional focus the FDA has in  building the capacity  of Local Pharmceutical Companies to International standards.

The participants also expressed their appreciation to the FDA for coming up with an excellent Training which has helped to build their capacity and skills as QPPV’s. (Below is the letter of appreciation from the Participants)

Dr. June Raine would also be making a presentation to the Managers of the Local Manufacturing Companies on the importance of Pharmacovigilence and the need to resource the QPPV’s to effectively carry out safety monitoring of their products at a Symposium to be held at 9am tomorrow, 6th October, 2017 at the Fiesta Royale Hotel, Accra.

Print Friendly